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Background: Asthma is one of the most common conditions which complicate pregnancy. Pro- and anti-apoptotic
mechanisms can be modulated by asthma accompanying pregnancy. Survivin, an anti-apoptotic protein has been
implicated in the pathomechanism of asthma and also in the development of pathological pregnancies; however
survivin has not been studied in pregnant asthmatics.
Methods: Twenty-eight asthmatic pregnant (AP), 25 asthmatic non-pregnant (ANP), 21 healthy pregnant (HP) and
29 healthy non-pregnant (HNP) women were enrolled in this cross-sectional study. Plasma survivin concentration
was determined by ELISA.
Results: Plasma survivin was significantly lower in HP (1.64 /0-74.9/ pg/ml) than in HNP (24.6 /0-333.3/ pg/ml,
p = 0.01). However, this difference was not observed between the asthmatic groups (p = 0.64). Similarly, there was
no difference either between HNP and ANP (10.5 /0-215.4/ pg/ml, p = 0.23) or between HP and AP (13.9 /0-364.1/
pg/ml, p = 0.30) groups.
Conclusions: Decreased plasma survivin levels in physiological but not in asthmatic pregnancy may suggest that
the normal apoptotic mechanisms are compromised in asthmatic gestation.
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Asthma is one of the most common disorders which may
complicate pregnancy and it represents an increased risk
for maternal and foetal complications, including pre-
eclampsia, gestational hypertension, preterm delivery,
Caesarean section, low birth weight, intrauterine growth
restriction and foetal death [1,2]. Asthma complicates
4-8% of pregnancies [2]. In addition, it is estimated that
one third of asthmatic women experience asthma wors-
ening during gestation [3]. The natural course of asthma
during pregnancy is currently unpredictable due to the
fact that the underlying pathophysiology is not fully elu-
cidated. Regulation of apoptosis is a potential way to
suppress immune activation during pregnancy. Pro-
apoptotic mediators are released from the placenta and
can be involved in the induction of increased T cell* Correspondence: andras.bikov@gmail.com
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unless otherwise stated.apoptosis [4,5]. Circulating apoptotic bodies and micro-
particles are possible mediators for these apoptotic sig-
nals during gestation [6]. In result, an increased
prevalence of apoptotic (CD95+) T cells is reported in
healthy pregnant compared to healthy non-pregnant
women [7]. Interestingly, recent studies reported dis-
turbance in the pro- and anti-apoptotic balance when
gestation accompanied by asthma [7,8]; however this
has not been studied in details.
Recent research focused on the role of anti-apoptotic
Birc5 protein, also known as survivin, in physiological and
pathological pregnancies. For brevity, we will henceforth
refer to Birc5/survivin as survivin. Survivin is a member
of the inhibitor-of-apoptosis family which inhibits the
caspase-regulated apoptotic pathway [9]. It plays an essen-
tial role during foetal life by regulating normal cytotropho-
blast development [10,11] and survivin is highly expressed
in various malignancies [12]. Its function in adult differen-
tiated cells is not fully known, but it may regulate activa-
tion and proliferation of T cells [13].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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trophoblast and weakly in syncytiotrophoblast cells of
the placenta [10]. It is responsible for cytotrophoblast
survival by regulating cell mitosis [11]. Its role in patho-
logical pregnancies is controversial. In hydatidiform
moles and choriocarcinomas survivin levels were ele-
vated [10,14] while in preeclampsia decreased expression
has been reported [11,15]. Although no study has exam-
ined circulating survivin concentration in pregnancy, it
is hypothesised that survivin levels are decreased as a
consequence of up-regulated pro-apoptotic processes.
Survivin may also be involved in chronic inflammatory
diseases such as bronchial asthma. Extracellular survivin
promotes the differentiation of T cells toward Th2 line
and enhances the production of some type 2 cytokines,
including IL-4 and IL-13 [16]. The gene expression of
survivin increases in ovalbumin-induced asthmatic mice
[17,18] and in induced sputum samples of asthmatic pa-
tients [19]. Moreover, sputum survivin mRNA levels are
related to airway eosinophilia [19]. Interestingly, certain
single nucleotide polymorphisms of the survivin gene
are more likely associated with asthma in women [19].
However, survivin is difficult to investigate in asthmatic
pregnancy as direct airway sampling methods, such as
bronchial biopsy or bronchoalveolar lavage, are invasive
and cannot be performed. Similarly, placental sampling
also carries risk for complications. The analysis of circulat-
ing survivin is a harmless and promising method to study
survivin-related processes [20-23], especially in solid tu-
mours and leukaemia [20]. However plasma survivin has
not been studied either in pregnancy or in asthma before.
As survivin is involved in asthma and pathological
pregnancy, we hypothesised that it may be altered in
asthmatic gestation. To investigate this, plasma survivin




Twenty-eight asthmatic pregnant (AP, 31 ± 5 years), 25
asthmatic non-pregnant (ANP, 32 ± 7 years), 21 healthy
pregnant (HP, 31 ± 5 years) and 29 healthy non-pregnant
(HNP, 30 ± 5 years) women were enrolled. The AP group
comprised volunteers in the 2nd trimester (N = 19, 20 ± 5
gestational weeks) or 3rd trimester (N = 9, 34 ± 4 gesta-
tional weeks), while the HP group consisted of participants
in the 2nd trimester (23 ± 3 gestational weeks). All volun-
teers were Caucasian except for one AP women who had
Asian origin.
Asthmatic patients were recruited at the outpatient
clinic of Department of Pulmonology. Asthma was diag-
nosed by a respiratory medicine specialist according to
the Global Initiative for Asthma (GINA) guidelines.
Asthmatic patients with exacerbations within the last6 months were not included. Nineteen ANP and fifteen
AP subjects used inhaled corticosteroids regularly, while
others were considered steroid-naive. The asthma was
considered well-controlled or partially controlled in 13
ANP and 14 AP subjects and uncontrolled in 12 and 14
subjects, respectively.
Pregnant women were recruited at the First Depart-
ment of Obstetrics and Gynecology. In all cases, the
pregnancy and labour were uncomplicated and pregnant
women gave birth to healthy children. Volunteers with
twin pregnancies or in whom later preeclampsia devel-
oped were not studied. HNP volunteers were workers
and students of Semmelweis University.
Subjects with any chronic disease, including hyperten-
sion, diabetes or malignancies were excluded. None of
the participants were current or ex-smokers or had any
respiratory tract infection within 4 weeks of the study.
Study design
In all subjects, venous blood was collected in EDTA-tubes.
In eight 2nd-trimester asthmatic pregnant volunteers, sam-
ple collection was repeated in the 3rd trimester (in the
cross-sectional analysis only the sample from the 2nd tri-
mester was used). In asthmatic subjects, additional lung
function and fractional exhaled nitric oxide (FENO) [24]
measurements were performed and asthma control was
evaluated with the Asthma Control Test (ACT) [25].
The study was approved by the Semmelweis University
Ethics Committee (TUKEB 110/2007), and all patients
gave written informed consent prior to participation in
the study.
Plasma survivin measurements
Plasma was separated according to the ELISA kit guidelines
and stored at −80°C until survivin measurements. Plasma
survivin levels were determined by a commercially available
ELISA kit (DSV00, R&D Systems, Abingdon, UK). The
detection limit was 4.44 pg/ml, as it was reported by the
manufacturer. The mean intra-assay coefficient for vari-
ation of duplicate samples was 22%.
Statistical analysis
We used Graphpad Prism 4.0 (GraphPad Software Inc.,
San Diego, CA, USA) for statistical analysis. The normality
distribution of the data was assessed by Kolmogorov–
Smirnov test. Plasma survivin was compared among
groups with two-way ANOVA followed by Bonferroni
post hoc test. Unpaired t-test was applied to compare
lung function variables, steroid use and neonatal birth
weight, while Mann–Whitney test was used to compare
FENO and ACT levels. The relationship between survivin
levels and clinical variables was analysed with Spearman
tests. Pearson and Spearman tests were used to correlate
clinical variables within groups. Since plasma survivin as
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variables were expressed as median/range/, otherwise as
mean ± SD. Samples with plasma survivin levels below
the detection limit were assigned to have 0 pg/ml of sur-
vivin. p < 0.05 was considered significant.
The sample size was calculated to find differences in
plasma survivin levels among the four groups using an
effect size of 0.35 and a statistical power (1-β) of 0.80
taking into account the asymptotic relative efficiency of
non-parametric tests [26].
Results
Comparison of the four groups
The two asthmatic groups (AP and ANP) were compar-
able in terms of lung function, inhaled corticosteroid
use, FENO and asthma control (all p > 0.05). Similarly,
there was no difference in neonatal birth weight, week of
delivery or in the 0- and 5-minute Apgar scores between
the AP and HP groups (all p > 0.05, Table 1).
Circulating survivin levels and their relationship to clinical
parameters
Survivin was detectable in 61% of AP, 43% of HP, 68% of
ANP and 72% of HNP women. Comparing the four
groups using two-way ANOVA, significantly lower plasma
survivin levels were noted in pregnancy (p = 0.04), how-
ever asthma had no effect (p = 0.59). Bonferroni post hoc
test revealed that pregnancy-related differences were
present only in healthy groups (1.64/0-74.9 pg/ml/ vs. 24.6
/0-333.3/ pg/ml, p = 0.01, HP vs. HNP, respectively), while
there was no difference when the asthmatic non-pregnant
(10.5 /0-215.4/ pg/ml) and asthmatic pregnant (13.9/0-
364.1/) patients were compared (p = 0.64). If the 3 out-
liers in the AP group were excluded the difference between
the 4 groups was still significant (p < 0.01). Comparing





FEV1; L 2.9 ± 0.4 2.8 ± 0.7
(% pred) (90 ± 11) (88 ± 18)
FVC; L 3.6 ± 0.5 3.7 ± 0.8
(% pred) (99 ± 13) (100 ± 15)
FENO; ppb 19 (8–115) 19 (5–82)
ACT 20 (8–25) 20 (9–25)
ICS; BDP eq. 200 (0–2000) 400 (0–1000
Neonatal birth weight; g 3548 ± 714 NA
Apgar; 1 and 5 minutes 9 and 10 NA
Week of delivery 39 (36–42) NA
AP: asthmatic pregnant, ANP: asthmatic non-pregnant, HP: healthy pregnant, HNP:
dipropionate equivalent, FENO: fractional exhaled nitric oxide, FEV1: forced expirator
NA: not applicable, ND: not determined, ppb: particles per billion. Data are expressesubjects no difference was found either between preg-
nant (p = 0.30) or non-pregnant (p = 0.23) groups
(Figure 1). When AP patients only in the 2nd trimester
were compared to HP volunteers the difference was still
not significant (p = 0.25).
There was no difference between AP subjects in the 2nd
(17.8 /0-364.1/ pg/ml) and 3rd trimester (0 /0-185.0/ pg/ml,
p = 0.61). Nor were the survivin levels in the same indivi-
dual (8 AP subjects) different between the two time points
(13.1 /0-31.6/ pg/ml vs. 6.6 /0-121.0/ pg/ml, 2nd vs. 3rd tri-
mester, respectively, p = 0.79, Figure 2). This indicates that
differences in gestational age between the AP and HP
groups did not bias the results on survivin. Comparing sur-
vivin levels depending on newborn gender there was no dif-
ference either in AP (p = 0.47) or HP (p = 0.45) groups.
The relationships between plasma survivin levels and
lung function variables, FENO or asthma control in the
AP and ANP groups were not significant (all p > 0.05).
Nor was there any relationship between plasma survivin
and gestational weeks or neonatal birth weight in either
of the AP and HP groups (all p > 0.05). Comparing
asthmatic patients using inhaled corticosteroids (ICS)
with steroid-naive subjects, no difference was observed
in plasma survivin either in the ANP (p = 0.80) or AP
groups (p = 0.58). Similarly, there was no relationship be-
tween ICS dose and plasma survivin levels either in
ANP (p = 0.19) or AP (p = 0.69) subjects.
Relationship between clinical variables
In the ANP group a significant relationship was found
between FEV1 and ACT (r = 0.43, p = 0.03) and there
was a statistical tendency for inverse correlation between
FEV1 and FENO levels (r = −0.44, p = 0.06). Interestingly,
these correlations were not present in AP subjects either













) NA NA 0.25
3442 ± 320 NA 0.59
9 and 10 NA 0.27 and 0.95
39 (36–41) NA 0.44
healthy non-pregnant, ACT: asthma control test, BDP eq.: beclomethasone
y volume in one second, FVC: forced vital capacity, ICS: inhaled corticosteroid,
d as mean ± SD or median (range).
Figure 1 Plasma survivin levels in the four groups. Plasma
survivin levels were significantly lower in HP subjects compared to
HNP volunteers. AP: asthmatic pregnant, ANP: asthmatic non-pregnant,
HP: healthy pregnant, HNP: healthy non-pregnant.
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In the current study we investigated plasma survivin
levels in asthma, together with asthmatic and healthy
pregnancies. We found that circulating survivin is de-
creased during gestation, which was blunted in asth-
matic pregnancy.
This is the first study analysing circulating survivin
levels in pregnancy, however the intracellular expression
during gestation has already been investigated in physio-
logical and pathological circumstances. It is known that
this molecule is produced by the placenta and has an
important role in the normal cytotrophoblast develop-
ment [10,11]. Its expression is tightly regulated as both
increased and reduced productions are associated with
pathological pregnancies [10,11,14,15].
The source and function of extracellular survivin in
pregnancy is not known. It may originate from dead
cells, but survivin can also be actively released by living
cells [27]. In malignancies, extracellular survivin is taken
up by the surrounding cancer cells inhibiting their apop-
tosis, accelerating their proliferation and increasing their
invasive potential [27]. A recent study described that
survivin produced by cancer cells also inhibits T cellFigure 2 Plasma survivin levels in the 2nd and 3rd trimesters of asthm
the 2nd and 3rd trimesters either when 2nd and 3rd trimester asthmatic preg
changes were assessed in eight subjects (Panel B).activation and proliferation [16]. Hence, decreased survi-
vin levels in pregnancy may be associated with enhanced
T cell activation. Supporting this, we have previously re-
ported that non-asthmatic pregnancy is associated with
activation and apoptosis of T cells [7]. Survivin affects
lymphocyte subtypes in different ways. It decreases the
number and suppresses the function of CD8+ T cells,
skewing immunity towards the Th2 direction, but not al-
tering the regulatory T cell and Th17 ratios [16]. In
addition, IFN-γ and IL-2 levels are decreased while IL-4
and IL-13 concentrations are increased in the presence
of survivin [16]. It is known that healthy pregnancy is as-
sociated with altered T cell balance [28] and cytokine
profiles [29] with elevated proportions of CD8+ cells
[28] and decreased levels of IL-4 [29].
Another possible reason for low extracellular survivin
in pregnancy might be the reduced production of vascu-
lar endothelial growth factor (VEGF) [30]. It is known
that the expression of survivin is induced by VEGF [31]
which is supported by a significant relationship between
plasma survivin and VEGF levels [21]. Finally, it is
known that survivin is down-regulated by progesterone
[32] the level of which is highly elevated during gesta-
tion. As we only investigated pregnant subjects in the
2nd and 3rd trimesters, we do not known if extracellular
survivin is equally low during the whole course of preg-
nancy. Only one study measured placental survivin
mRNA, showing reducing levels throughout the preg-
nancy [15]. We did not find significant differences in
survivin levels between the 2nd- and 3rd-trimester preg-
nant asthmatics, however this analysis was poorly pow-
ered in the current study and we cannot rule out the
possibility that survivin levels may change in non-
asthmatic pregnant subjects.
Asthma may modulate pregnancy-related immune re-
sponses [28,33]. For instance, CD8+ T cell prevalence is
decreased [28], while IL-4 and IFN-γ levels are elevated
[33] in asthmatic gestation. The absence of a physio-
logical decrease in survivin levels in asthmatic pregnancy
may contribute to these immunological changes. None-
theless, IFN-γ, known to be increased in asthmaticatic pregnancy. There was no difference in plasma survivin between
nant women were compared (Panel A) nor when the temporal
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contributing to its blunted decrease seen in the current
study.
In addition, various studies suggest that asthma also
suppresses the anti-apoptotic mechanism seen in physio-
logical pregnancy. We have previously described that
lymphocyte apoptosis is enhanced in healthy pregnancy;
however this effect is limited in asthmatic pregnant
women [7]. Similarly, another anti-apoptotic agent [34],
heat shock protein 70 was also found to be decreased in
normal pregnancy [35], but not in asthmatic pregnant
women [8]. Our present results are consistent with these
previous findings.
Recent studies supported the role of survivin in the
pathomechanism of asthma [17-19]. We could not find
any differences between asthmatic and non-asthmatic
subjects either when the pregnant or non-pregnant
women were compared. Similarly, there was no corre-
lation with any of the asthma variables. This might sug-
gest that survivin-related asthmatic processes are
localised in the lungs, as in the previous human study,
only airway samples were analysed [19]. In the present
study, asthmatic subjects with recent exacerbation were
excluded, and asthma was considered relatively stable in
participants. Despite the fact that there was no asso-
ciation between survivin levels and clinical variables of
asthma, we cannot exclude the possibility that height-
ened disease activity (i.e. during exacerbation) might be
related with increased systemic survivin. Of note, in-
creased survivin in induced sputum samples of asth-
matic patients was noted even in stable subjects [19].
Only a few studies have examined plasma survivin to
date in various diseases including solid tumours, leukae-
mia, rheumatoid arthritis and HCV infection [20-23]. In
overall, the median values were very close to the lower
limit of detection with around 30% of the samples below
the limit of detection which is in line with the observa-
tions of the current study. Survivin was even more
poorly detectable in pregnancy which further confirms
that this molecule is decreased during gestation, but un-
fortunately this also limits the statistical power of our
conclusions. Previous studies measured survivin in
plasma samples with ELISA which is a more feasible
method to analyse survivin in <100 pg/ml concentration
range than Western blot which has a detection limit
around 100 pg/ml in plasma samples. Two studies used
the same commercially available ELISA kit as in our
study [21,23], but unfortunately neither of them reported
intra-assay variability. The relatively poor analytical re-
peatability of this analytical method and the high propor-
tion of samples with survivin concentration below the
detection limit may not allow to draw final conclusions
from some analyses done on small number of samples
(i.e. the effect of gestational age or clinical outcomes ofasthma or gestation). Therefore, the results on these
statistics should be interpreted carefully. Of note, fur-
ther studies are warranted to optimise the medium
(serum, EDTA or citrate plasma) for survivin measure-
ments, as the healthy values tended to be higher in a
previous study using citrate tubes than in our results
measured in samples collected in EDTA tubes [23].
Conclusions
In summary, for the first time, we reported significantly
lower levels of plasma survivin in physiological but not
in asthmatic gestation. Further studies are warranted to
fully investigate the influence of survivin on apoptotic
and immunological processes in pregnancy.
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